VNDA - Vanda Pharma Debt to Book Capitalization Ratio

Vanda Pharmaceuticals (VNDA) maintains strong niche positions in the psychoneurology sector, protecting profits with patents against cheap generics. Revenues are based on sleep correction agents, although the risk of losing exclusive rights creates volatility, which currently stands at 0.10. The market price action of the securities is presented below; meanwhile, Vanda Pharmaceuticals (VNDA) is implementing eco-friendly synthesis methods and strictly adhering to medical trial ethics.

VNDA (Vanda) Debt to Book Value history from 07/04/2022 to 10/28/2026

Vanda Pharma (VNDA) - metric breakdowns and financial figures

- price and consensus price forecast:

Stock Price Vanda Pharmaceuticals|VNDA - Analyst Consensus Forecast

- market capitalization data:

Market Value Vanda|VNDA - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share Vanda Pharmaceuticals|VNDA - Company Net Assets|Market Capitalization to Book Value Ratio vandapharma.com|VNDA - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Vanda Pharmaceuticals|VNDA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Vanda Pharmaceuticals Inc|VNDA - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Vanda

Summary company analytics:Vanda Pharmaceuticals

Core merchandise of Vanda Pharmaceuticals Inc

The erosion of patent protection for Vanda Pharmaceuticals (VNDA) products is forcing the company to optimize its capital structure to maintain competitiveness. This debt-to-book capitalization ratio measures the proportion of borrowed funds within the total capital, allowing investors to quickly assess the risk of insolvency or the pace of leverage-driven expansion, which is critical during a decline in the market value of assets.

Competitors of Vanda Pharmaceuticals (VNDA)